The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 4, 2010, Pages 280-286

  Abdul Ghani, Muhammad A ^a   Lyssenko, Valeriya ^b   Tuomi, Tiinamaija ^b   DeFronzo, Ralph A ^a   Groop, Leif ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b LUND UNIVERSITY DIABETES CENTRE   (Sweden)

Author keywords

OGTT; Prediction of diabetes; Shape of glucose tolerance curve

Indexed keywords

ADULT; AREA UNDER THE CURVE; ARTICLE; CELL FUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RISK ASSESSMENT;

AGE FACTORS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; CHOLESTEROL; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MALE; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 77952748876     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1084     Document Type: Article

References (23)

1. Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention. Diabet Med 2002; 19: 708-723.
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabet Care 1997; 20: 1183-1197.
3. Shaw J, Zimmet P, de Courten M, et al. Impaired fasting glucose or impaired glucose tolerance: what best predicts future diabetes in Mauritius? Diabet Care 1999; 22: 399-402. (Pubitemid 29106893)
4. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. Diabet Care 1998; 21: 1686-1690.
5. Gabir MM, Hanson RL, Dabelea D, et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabet Care 2000; 23: 1113-1118.
6. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006; 55: 1430-1435.
7. Abdul-Ghani MA, Jenkinson C, Richardson D, DeFronzo RD. Impaired early but not late phase insulin secretion in subjects with impaired fasting glucose. Eur J Clin Invest 2008; (in press).
8. Zhou W, Gu Y, Li H, Luo M. Assessing 1-h plasma glucose and shape of the glucose curve during oral glucose tolerance test. Eur J Endocrinol 2006; 155: 191-197.
9. Kanauchi M, Kimura K, Kanauchi K, Saito Y. Beta-cell function and insulin sensitivity contribute to the shape of plasma glucose curve during an oral glucose tolerance test in non-diabetic individuals. Int J Clin Pract 2005; 59: 427-432.
10. Tschritter O, Fritsche A, Shirkavand F, Machicao F, Häring H, Stumvoll M. Assessing the shape of the glucose curve during an oral glucose tolerance test. Diabet Care 2003; 26: 1026-1033.
11. Abdul-Ghani MA, Williams K, DeFronzo R, Stern M. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabet Care 2006; 29: 1613-1618.
12. Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 1996; 45: 1585-1593. (Pubitemid 26357553)
13. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
14. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic glucose clamp. Diabet Care 1999; 22: 1462-1470.
15. Nathan DM, Davidson MB, DeFronzo RA, et al. American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabet Care 2007; 30: 753-759.
16. DeFronzo RA. Lilly Lecture 1987: the triumvirate: ß-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
17. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabet Care 2006; 29: 1130-1139.
18. Bergman RN, Finegood DT, Kahn SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002; 32(Suppl 3): 35-45. (Pubitemid 41704998)
19. Bogardus C, Tataranni PA. Reduced early insulin secretion in the etiology of type 2 diabetes mellitus in Pima Indians. Diabetes 2002; 51(Suppl 1): S262-S264. (Pubitemid 34761526)
20. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabet Care 2007; 30: 89-94.
21. Hanley AJ, Williams K, Gonzalez C, et al. Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes 2003; 52: 463-469. (Pubitemid 36173204)
22. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794. (Pubitemid 29536364)
23. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabet Care 2007; 30: 1544-1548.